For research use only. Not for therapeutic Use.
Nifeviroc（Cat No.:I008293）is a potent CCR5 receptor antagonist developed as an investigational drug for the treatment of HIV infection. By selectively blocking the CCR5 co-receptor on immune cells, Nifeviroc prevents the entry of HIV into host cells, thus inhibiting viral replication. This mechanism targets a key pathway used by certain strains of HIV, offering a therapeutic approach for managing the virus in patients with CCR5-tropic HIV-1. Nifeviroc’s ability to block viral entry without affecting other immune functions makes it a promising candidate in HIV treatment research.
| Catalog Number | I008293 |
| CAS Number | 934740-33-7 |
| Synonyms | TD-0232; TD0232; TD 0232;4-nitrobenzyl allyl(1-(((3S,4R)-1-(cyclopentanecarbonyl)-4-hydroxy-4-phenylpyrrolidin-3-yl)methyl)piperidin-4-yl)carbamate |
| Molecular Formula | C33H42N4O6 |
| Purity | ≥95% |
| Target | Immunology/Inflammation |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| IUPAC Name | (4-nitrophenyl)methyl N-[1-[[(3S,4R)-1-(cyclopentanecarbonyl)-4-hydroxy-4-phenylpyrrolidin-3-yl]methyl]piperidin-4-yl]-N-prop-2-enylcarbamate |
| InChI | InChI=1S/C33H42N4O6/c1-2-18-36(32(39)43-23-25-12-14-30(15-13-25)37(41)42)29-16-19-34(20-17-29)21-28-22-35(31(38)26-8-6-7-9-26)24-33(28,40)27-10-4-3-5-11-27/h2-5,10-15,26,28-29,40H,1,6-9,16-24H2/t28-,33-/m0/s1 |
| InChIKey | JNSKQYZFEVKYDB-UVMMSNCQSA-N |
| SMILES | C=CCN(C1CCN(CC1)C[C@H]2CN(C[C@@]2(C3=CC=CC=C3)O)C(=O)C4CCCC4)C(=O)OCC5=CC=C(C=C5)[N+](=O)[O-] |
| Reference | 1:J Pharm Biomed Anal. 2011 Nov 1;56(3):637-40. doi: 10.1016/j.jpba.2011.06.027. Epub 2011 Jul 5. Determination of nifeviroc, a novel CCR5 antagonist: application to a pharmacokinetic study.Wu W,Xie D,Cheng Z,Liu Z,Ran L,Gu Z,Yu P, PMID: 21802236 DOI: 10.1016/j.jpba.2011.06.027 </br><span>Abstract:</span> Nifeviroc is a novel CCR5 antagonist used for the treatment of HIV type-1 infection. A LC-ESI-MS/MS method for the determination of nifeviroc in human plasma was developed and validated. The calibration curve (r(2)=0.9993) of nifeviroc was established at the range of 1.924-2935 μg L(-1). The intra- and inter-day precisions (RSD%) were all less than 7%, and the accuracies at three concentration levels were all within 100 ± 5%. This validated method was then successfully applied to a pharmacokinetic study in health Chinese volunteers.Copyright © 2011 Elsevier B.V. All rights reserved. |
